Positive pre-clinical proof of concept in MS fatigue model
Chronos announces positive pre-clinical results for the lead compound in its DAT inhibitor programme in an in vivo model of fatigue in multiple sclerosis (MS). Read the press release.
Positive pre-clinical proof of concept studies in orexin-1 antagonist project
Chronos has demonstrated positive pre-clinical proof of concept (POC) results for the lead compound in its orexin-1 antagonist programme in an in vivo model of binge eating disorder (BED). Read [...]
Patent filed for novel orexin 1 antagonist programme
A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]
Chronos announces partnership with Aptuit for addictive behaviour programmes
Chronos announces a major partnership with Aptuit Verona, Italy for specific orexin 1 antagonist programme. Read the press release.